Stereotactic versus whole-brain radiotherapy combined with immunotherapy in driver gene–negative NSCLC with brain metastases: a real-world IPTW analysis - Scorecard - MDSpire
Advertisement
Stereotactic versus whole-brain radiotherapy combined with immunotherapy in driver gene–negative NSCLC with brain metastases: a real-world IPTW analysis
Clinical Scorecard: Comparative Efficacy of Stereotactic Radiotherapy and Whole-Brain Radiotherapy with Immunotherapy in Driver Gene-Negative NSCLC Patients with Brain Metastases: An IPTW Analysis from Real-World Data
At a Glance
Category
Detail
Condition
Driver gene-negative non-small cell lung cancer with brain metastases
Key Mechanisms
Combination of immune checkpoint inhibitors with radiotherapy
Target Population
Patients with driver gene-negative NSCLC and brain metastases
Care Setting
Oncology treatment centers
Key Highlights
SRT+I associated with superior overall survival compared to WBRT+I (29.3 vs. 19.9 months)
SRT+I showed better intracranial progression-free survival (14.7 vs. 9.4 months)
Higher intracranial objective response rate with SRT+I (78.6% vs. 61.5%)
Lower incidence of radiation-induced brain injury in SRT+I group (3.75% vs. 10.26%)
No grade ≥3 immune-related adverse events reported in SRT+I group
Guideline-Based Recommendations
Diagnosis
Confirm NSCLC diagnosis and absence of driver gene mutations
Use contrast-enhanced MRI to confirm brain metastases
Management
Consider SRT+I for improved survival outcomes in driver gene-negative NSCLC with BMs
Monitoring & Follow-up
Regular follow-up imaging to assess intracranial disease control
Risks
Monitor for potential radiation-induced brain injury and immune-related adverse events
Patient & Prescribing Data
158 patients with driver gene-negative NSCLC and brain metastases
Immunotherapy administered after radiotherapy yields superior survival outcomes
Clinical Best Practices
Utilize IPTW to balance baseline variables in treatment comparisons
Evaluate treatment efficacy through Kaplan-Meier analysis and Cox regression
